Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older with Retinitis Pigmentosa
- Conditions
- Retinitis Pigmentosa
- Interventions
- Drug: DSP-3077 Retinal Sheet Cohort 1Drug: DSP-3077 Retinal Sheet Cohort 2Drug: DSP-3077 Retinal Sheet Cohort 3
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06891885
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
- Conditions
- Parkinson's Disease
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT06753331
- Locations
- 🇺🇸
New York Presbyterian Hospital-Columbia University Medical Center, New York, New York, United States
🇺🇸University of Kentucky Medical Center, Lexington, Kentucky, United States
SMP-3124LP in Adults With Advanced Solid Tumors
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06526819
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)
- Conditions
- Retinitis Pigmentosa
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06517940
- Locations
- 🇺🇸
Mass Eye and Ear, Boston, Massachusetts, United States
Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06389955
- Locations
- 🇺🇸
Frontage Investigative Site, Secaucus, New Jersey, United States
A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.
- Conditions
- Social Anxiety Disorder (SAD)
- Interventions
- Device: BVR-100Device: BES-100
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06037668
- Locations
- 🇺🇸
Alivation Health, LLC, Lincoln, Nebraska, United States
🇺🇸CNS Healthcare, Orlando, Florida, United States
🇺🇸Cedar Clinical Research, Draper, Utah, United States
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05741528
- Locations
- 🇺🇸
Advanced Research Center Inc., Anaheim, California, United States
🇺🇸Collaborative Neuroscience Research, LLC, Torrance, California, United States
🇺🇸Clinical Innovations, Inc., Riverside, California, United States
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
- Conditions
- Depressive Episodes, Bipolar I Depression
- Interventions
- Drug: SEP-4199 CR
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05227209
- Locations
- 🇺🇸
University of Alabama at Birmingham Huntsville Regional Medical Campus, Huntsville, Alabama, United States
🇺🇸Advanced Research Center, Inc., Anaheim, California, United States
🇺🇸Sun Valley Research Center, Imperial, California, United States
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
- Conditions
- Depressive Episodes, Bipolar I Depression
- Interventions
- Drug: SEP-4199 CR 200 mgDrug: SEP-4199 CR 400 mgDrug: Placebo
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT05169710
- Locations
- 🇺🇸
University of Alabama at Birmingham Huntsville Regional Medical Campus, Huntsville, Alabama, United States
🇺🇸Sanro Clinical Research Group LLC, Bryant, Arkansas, United States
🇺🇸Advanced Research Center, Inc., Anaheim, California, United States
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
- Conditions
- Glioblastoma MultiformeHigh Grade Glioma
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT05023551
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States